A cataract expert discussed if postoperative topical antibiotics add protection after intracameral prophylaxis.

At AAO 2026, Michael T. Yen, MD, explained how at-home subcutaneous elegrobart could ease treatment burden in thyroid eye disease.

Uveitis is uncommon, but it causes a disproportionate share of visual morbidity.

Anjum F. Koreishi, MD, explains why inflammation control and planning are key to cataract surgery for patients with uveitis.

FDA accepts vamikibart BLA for UME as data show sustained gains at 1 year; decision July 2027.

Timothy Janetos, MD, outlined can’t-miss uveitis diagnoses, warning signs, and why every new patient needs dilation.

At AAO 2026, Michael T. Yen, MD, reviewed REVEAL-1 efficacy and hearing safety data for subcutaneous elegrobart in active TED.

Oral PKC inhibitor darovasertib preserved the eye in 57% of patients facing enucleation and cut projected radiation doses in 70.3% in the phase 2 OptimUM-09 trial.